Shivakumar, O;
Sattar, N;
Wheeler, DC;
(2020)
Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease.
Nephrology Dialysis Transplantation
, 35
(S1)
i43-i47.
10.1093/ndt/gfz292.
Preview |
Text
Wheeler_gfz292.pdf - Published Version Download (254kB) | Preview |
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events, specifically those related to heart failure in patients with type 2 diabetes. Reductions in major adverse cardiovascular event (MACE) outcomes are also observed, but confined largely to patients who have prior cardiovascular disease. Cardiovascular outcome benefits extend to patients with type 2 diabetes and reduced estimated glomerular filtration (eGFR) rate down to 30 mL/min/1.73 m2 and to patients with heart failure but without diabetes. Ongoing trials are exploring whether patients with chronic kidney disease (CKD) but without diabetes will gain similar benefits from this class of agents. Although some safety concerns have emerged, it seems likely that SGLT2 inhibitors will be used more widely in CKD patients to reduce their cardiovascular risk.
| Type: | Article |
|---|---|
| Title: | Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/ndt/gfz292 |
| Publisher version: | https://doi.org/10.1093/ndt/gfz292 |
| Language: | English |
| Additional information: | Copyright © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| Keywords: | SGLT2 inhibitors, cardiovascular disease, chronic kidney disease, heart failure, type 2 diabetes |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10090892 |
Loading...
Loading...Loading...| 1. |  United States | 5 |
| 2. |  Germany | 1 |
| 3. |  Russian Federation | 1 |
Archive Staff Only
 |
View Item |
